Krka d. d
Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. The company's prescription pharmaceuticals include medicines for the treatment of cardiovascular, gastrointestinal tract and metabolis… Read more
Krka d. d (KRK) - Net Assets
Latest net assets as of September 2025: zł2.31 Billion PLN
Based on the latest financial reports, Krka d. d (KRK) has net assets worth zł2.31 Billion PLN as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (zł2.97 Billion) and total liabilities (zł662.58 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | zł2.31 Billion |
| % of Total Assets | 77.67% |
| Annual Growth Rate | 5.53% |
| 5-Year Change | 27.74% |
| 10-Year Change | 59.16% |
| Growth Volatility | 3.15 |
Krka d. d - Net Assets Trend (2010–2024)
This chart illustrates how Krka d. d's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Krka d. d (2010–2024)
The table below shows the annual net assets of Krka d. d from 2010 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | zł2.24 Billion | +2.57% |
| 2023-12-31 | zł2.18 Billion | +2.02% |
| 2022-12-31 | zł2.14 Billion | +11.43% |
| 2021-12-31 | zł1.92 Billion | +9.55% |
| 2020-12-31 | zł1.75 Billion | +5.06% |
| 2019-12-31 | zł1.67 Billion | +8.26% |
| 2018-12-31 | zł1.54 Billion | +3.53% |
| 2017-12-31 | zł1.49 Billion | +2.99% |
| 2016-12-31 | zł1.44 Billion | +2.74% |
| 2015-12-31 | zł1.41 Billion | +4.00% |
| 2014-12-31 | zł1.35 Billion | +1.45% |
| 2013-12-31 | zł1.33 Billion | +7.42% |
| 2012-12-31 | zł1.24 Billion | +8.84% |
| 2011-12-31 | zł1.14 Billion | +8.21% |
| 2010-12-31 | zł1.05 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Krka d. d's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 161.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | zł2.24 Billion | 100.79% |
| Common Stock | zł54.73 Million | 2.47% |
| Other Comprehensive Income | zł-14.57 Million | -0.66% |
| Total Equity | zł2.22 Billion | 100.00% |
Krka d. d Competitors by Market Cap
The table below lists competitors of Krka d. d ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Worley Limited
PINK:WYGPF
|
$4.31 Billion |
|
Kodiak Gas Services, Inc.
NYSE:KGS
|
$4.31 Billion |
|
SFS Group AG
SW:SFSN
|
$4.31 Billion |
|
TECHNIP ENERGIES EO -01
F:68F
|
$4.32 Billion |
|
HMM Co Ltd
KO:011200
|
$4.30 Billion |
|
RIOT PLATFORMS DL-001
F:AP4N
|
$4.30 Billion |
|
Vista Oil & Gas S.A.B. de C.V
PINK:VSOGF
|
$4.30 Billion |
|
ELF Beauty Inc
NYSE:ELF
|
$4.30 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Krka d. d's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,162,055,000 to 2,218,183,000, a change of 56,128,000 (2.6%).
- Net income of 356,986,000 contributed positively to equity growth.
- Dividend payments of 230,884,000 reduced retained earnings.
- Share repurchases of 25,002,000 reduced equity.
- Other comprehensive income decreased equity by 18,180,000.
- Other factors decreased equity by 26,792,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | zł356.99 Million | +16.09% |
| Dividends Paid | zł230.88 Million | -10.41% |
| Share Repurchases | zł25.00 Million | -1.13% |
| Other Comprehensive Income | zł-18.18 Million | -0.82% |
| Other Changes | zł-26.79 Million | -1.21% |
| Total Change | zł- | 2.60% |
Book Value vs Market Value Analysis
This analysis compares Krka d. d's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 13.71x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 31.75x to 13.71x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-12-31 | zł31.12 | zł988.00 | x |
| 2011-12-31 | zł33.89 | zł988.00 | x |
| 2012-12-31 | zł37.23 | zł988.00 | x |
| 2013-12-31 | zł40.34 | zł988.00 | x |
| 2014-12-31 | zł41.22 | zł988.00 | x |
| 2015-12-31 | zł43.16 | zł988.00 | x |
| 2016-12-31 | zł44.54 | zł988.00 | x |
| 2017-12-31 | zł46.15 | zł988.00 | x |
| 2018-12-31 | zł48.04 | zł988.00 | x |
| 2019-12-31 | zł52.41 | zł988.00 | x |
| 2020-12-31 | zł55.52 | zł988.00 | x |
| 2021-12-31 | zł61.09 | zł988.00 | x |
| 2022-12-31 | zł68.19 | zł988.00 | x |
| 2023-12-31 | zł69.85 | zł988.00 | x |
| 2024-12-31 | zł72.06 | zł988.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Krka d. d utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 16.09%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 18.69%
- • Asset Turnover: 0.67x
- • Equity Multiplier: 1.28x
- Recent ROE (16.09%) is above the historical average (13.64%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | 16.26% | 16.93% | 0.68x | 1.41x | zł65.85 Million |
| 2011 | 14.30% | 15.14% | 0.70x | 1.35x | zł48.98 Million |
| 2012 | 12.91% | 13.99% | 0.70x | 1.31x | zł36.01 Million |
| 2013 | 12.98% | 14.39% | 0.68x | 1.32x | zł39.71 Million |
| 2014 | 12.31% | 13.95% | 0.66x | 1.33x | zł31.16 Million |
| 2015 | 11.27% | 13.59% | 0.64x | 1.29x | zł17.77 Million |
| 2016 | 7.51% | 9.23% | 0.61x | 1.32x | zł-35.89 Million |
| 2017 | 10.26% | 12.05% | 0.66x | 1.29x | zł3.93 Million |
| 2018 | 11.35% | 13.11% | 0.67x | 1.29x | zł20.83 Million |
| 2019 | 14.75% | 16.44% | 0.68x | 1.31x | zł79.11 Million |
| 2020 | 16.69% | 18.96% | 0.69x | 1.28x | zł116.66 Million |
| 2021 | 16.23% | 19.75% | 0.62x | 1.33x | zł118.69 Million |
| 2022 | 17.15% | 21.15% | 0.64x | 1.27x | zł151.43 Million |
| 2023 | 14.52% | 17.38% | 0.65x | 1.28x | zł97.74 Million |
| 2024 | 16.09% | 18.69% | 0.67x | 1.28x | zł135.17 Million |
Industry Comparison
This section compares Krka d. d's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $439,847,293
- Average return on equity (ROE) among peers: 5.82%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Krka d. d (KRK) | zł2.31 Billion | 16.26% | 0.29x | $4.31 Billion |
| Celon Pharma SA (CLN) | $439.85 Million | 5.82% | 0.19x | $120.35 Million |